• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's Intraday Session

    4/24/24 12:31:39 PM ET
    $ADXN
    $ATHE
    $CMAX
    $EVO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Catheter Precision (AMEX:VTAK) shares moved upwards by 27.8% to $0.58 during Wednesday's regular session. The company's market cap stands at $4.4 million.
    • Prenetics Global (NASDAQ:PRE) stock moved upwards by 26.25% to $5.77. The company's market cap stands at $70.4 million.
    • Alterity Therapeutics (NASDAQ:ATHE) stock rose 15.02% to $2.45. The market value of their outstanding shares is at $21.3 million.
    • Immutep (NASDAQ:IMMP) shares increased by 13.54% to $2.85. The market value of their outstanding shares is at $338.8 million.
    • CareMax (NASDAQ:CMAX) shares rose 12.89% to $3.94. The market value of their outstanding shares is at $14.9 million.
    • SINTX Techs (NASDAQ:SINT) stock moved upwards by 12.84% to $0.04. The market value of their outstanding shares is at $4.9 million.

    Losers

    • GlucoTrack (NASDAQ:GCTK) shares decreased by 38.2% to $0.47 during Wednesday's regular session. The company's market cap stands at $12.5 million.
    • Evotec (NASDAQ:EVO) shares decreased by 31.9% to $5.21. The market value of their outstanding shares is at $1.8 billion. As per the news, the Q4 earnings report came out today.
    • Vaxxinity (NASDAQ:VAXX) stock fell 26.51% to $0.15. The market value of their outstanding shares is at $18.6 million.
    • Addex Therapeutics (NASDAQ:ADXN) shares fell 18.9% to $15.2. The market value of their outstanding shares is at $16.2 million. As per the news, the Q4 earnings report came out 4 days ago.
    • Kiora Pharmaceuticals (NASDAQ:KPRX) stock declined by 15.41% to $0.49. The market value of their outstanding shares is at $12.8 million.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 14.87% to $1.03. The market value of their outstanding shares is at $1.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ATHE
    $CMAX
    $EVO

    CompanyDatePrice TargetRatingAnalyst
    Prenetics Global Limited
    $PRE
    3/16/2026$29.00Buy
    Lake Street
    Immutep Limited
    $IMMP
    3/13/2026Buy → Hold
    Maxim Group
    Immutep Limited
    $IMMP
    3/13/2026$1.00Outperform → Neutral
    Robert W. Baird
    Immutep Limited
    $IMMP
    3/13/2026Mkt Outperform → Mkt Perform
    Citizens
    Immutep Limited
    $IMMP
    2/17/2026$6.00Mkt Outperform
    Citizens
    Prenetics Global Limited
    $PRE
    2/11/2026$36.00Buy
    Roth Capital
    Evotec SE
    $EVO
    2/3/2026Buy
    Berenberg
    Evotec SE
    $EVO
    4/24/2025Sell → Hold
    Deutsche Bank
    More analyst ratings

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

    Company prepares to file Investigational Device Exemption (IDE) for Novel CBGM Technology, targeting US Clinical Trial Launch in Second Half of 2026 US Patent and Trademark Office (USPTO) issued patents for Glucotrack's implantablecontinuous blood glucose monitoring (CBGM) technology, strengthening the Company'sintellectual property portfolio Rutherford, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year

    3/30/26 4:50:00 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program

    MELBOURNE, Australia and SAN FRANCISCO, March 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received positive regulatory feedback following a Type C Meeting with the U.S. Food and Drug Administration (FDA) regarding its planned Phase 3 development program for ATH434 in Multiple System Atrophy (MSA). The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its plans

    3/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins David A

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:17 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Anderson Philip J

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:15 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Arno Andrew

    4 - Catheter Precision, Inc. (0001716621) (Issuer)

    3/30/26 5:58:11 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    SEC Filings

    View All

    SEC Form 10-K filed by Catheter Precision Inc.

    10-K - Catheter Precision, Inc. (0001716621) (Filer)

    3/31/26 11:07:34 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    SEC Form F-3 filed by Prenetics Global Limited

    F-3 - Prenetics Global Ltd (0001876431) (Filer)

    3/31/26 9:24:53 AM ET
    $PRE
    Blank Checks
    Finance

    SEC Form 10-K filed by GlucoTrack Inc.

    10-K - Glucotrack, Inc. (0001506983) (Filer)

    3/30/26 5:39:10 PM ET
    $GCTK
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Prenetics Group Ltd. with a new price target

    Lake Street initiated coverage of Prenetics Group Ltd. with a rating of Buy and set a new price target of $29.00

    3/16/26 8:45:09 AM ET
    $PRE
    Blank Checks
    Finance

    Immutep downgraded by Maxim Group

    Maxim Group downgraded Immutep from Buy to Hold

    3/13/26 12:51:00 PM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immutep downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Immutep from Outperform to Neutral and set a new price target of $1.00

    3/13/26 8:45:21 AM ET
    $IMMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

    SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

    11/14/24 5:12:56 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Financials

    Live finance-specific insights

    View All

    Catheter Precision Reports 2025 Results and Updates on Strategic Expansion

    Clinical, Commercial and Regulatory Milestones Achieved in 2025 Establish a Strong Foundation in Life Sciences as Revenue Increases 95% Year Over Year Acquisition of Flyte and Strengthened Capital Position Unlock Multi-Segment Growth Strategy with Multiple Near-Term Catalysts FORT MILL, S.C., March 31, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK) ("VTAK" or the "Company"), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the fourth quarter and full year ended December 31, 2025 as well as certain other business updates. 2025: Execution Across Clin

    3/31/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    CRTD (Creatd Inc.) Sells Remaining 80% of Fly Flyte to NYSE-Listed VTAK (Catheter Precision Inc.), Securing Significant Cash and Equity Position

    NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Creatd, Inc. (OTCQB:CRTDD) today announced that it has sold its remaining 80% equity stake in its subsidiary, Fly Flyte, Inc. ("Flyte"), to Catheter Precision, Inc. (NYSE:VTAK). Under the terms of the completed transaction, Creatd will receive approximately $6,000,000 in cash and nearly $6,000,000 in Convertible Preferred Stock of VTAK. The NYSE-approved transaction considerably strengthens Creatd's balance sheet. The sale is consistent with Creatd's strategy of developing turnkey operating solutions that prepare businesses for listing on the public markets while simultaneously retaining a minority interest in them. The transaction positions Cr

    3/10/26 8:00:00 AM ET
    $VTAK
    Medical/Dental Instruments
    Health Care

    Prenetics Reports Record Q4 and FY 2025 Results: IM8 Achieves $120M ARR¹ in 12 Months, Revenue Surges 480% YoY

    Total Revenue Increased 480% to $92.4 million for Full Year 2025, Q4 Revenue reached $36.6 millionIM8 Reaches $10 Million in Monthly Revenue in December 2025, Achieving $120M ARR MilestoneStrategic Transformation Completed with Divestitures and Focus on IM8 Total Adjusted Liquidity2 of Approximately $171 Million Following Sale of Insighta Stake to Tencent, with Zero DebtCompany to Host Earnings Call on February 18, 2026, at 10:00 a.m. ET and latest investor deck can be found at https://ir.prenetics.com NEW YORK, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:PRE) ("Prenetics" or the "Company"), a leading consumer health sciences company and parent of the IM8 premium he

    2/18/26 9:11:26 AM ET
    $PRE
    Blank Checks
    Finance

    $ADXN
    $ATHE
    $CMAX
    $EVO
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Provides Corporate Business Update Highlighting First Human Implant, Strategic Transformation, and Commercial Execution

    Clinical milestone, new President appointment, and platform expansion position SINTX for commercial rollout and revenue growth in 2026 SALT LAKE CITY, Utah, March 23, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced biomaterials company focused on developing silicon nitride technologies for medical applications, today provided a corporate business update highlighting recent clinical, operational, and leadership milestones that the Company believes position it for commercial expansion and future revenue growth. The update follows a series of key developments, including the successful completion of the first human surgical procedure us

    3/23/26 9:15:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care